CombiGene
2.82 SEK +3.68%Be the first to follow this company
CombiGene's vision is to give patients affected by severe diseases the opportunity for a better life through gene therapy and other forms of advanced treatments. The company's operations have three focus areas: in-licensing of new assets, development of these assets to proof-of-concept, and out-licensing of the assets to a strategic partner for continued development and commercialization. CombiGene is based in Stockholm.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
COMBI
Daily low / high price
2.72 / 2.88
SEK
Market cap
55.84M SEK
Turnover
10.26K SEK
Volume
3.6K
Financial calendar
Interim report
08.11.2024
Annual report
14.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Orpahazyme AS | 10.0 % | 10.0 % |
Jan Ivar Nordqvist | 9.5 % | 9.5 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
BioStock: Continued focus on new licensing deals for CombiGene
Interim report January – June 2024 for CombiGene AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools